Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Periogen
- Development stage
- Phase 3
- Lead developer
- Periogen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implantation
01
Overview
Periogen is a therapeutic product composed of recombinant human Platelet-Derived Growth Factor (rhPDGF) and beta-tricalcium phosphate (beta-TCP). It is designed to promote gingival healing and correct periodontal defects, specifically intrabony periodontal defects, by stimulating tissue regeneration and providing a scaffold for bone formation.
- Brand names
- Periogen
- Other names
- rhPDGF-BB + beta-TCP
02
Targets
HydroxyapatitePDGFR (PDGFR family)
Beyond the preview
Go deeper on Periogen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Periogen.